Pancreatic Cancer Research

ResearcherHamamatsu UniversityActive in the last 2 years

Satoru Furuhashi

Matched on ORCID iD 0000-0001-8732-3491; OpenAlex author ID A5043363414. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 7

  1. SPARC is associated with tumor nerve stroma interactions and perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-026-51848-6↗
  2. Prognostic value of neutrophil to lymphocyte ratio in patients with advanced pancreatic ductal adenocarcinoma treated with systemic chemotherapy. Co-author DOI 10.1080/07853890.2024.2398725↗
  3. Tenascin C in pancreatic cancer-associated fibroblasts enhances epithelial mesenchymal transition and is associated with resistance to immune checkpoint inhibi… Co-author PMID 38058842↗
  4. Ephrin Receptor A4 Expression Enhances Migration, Invasion and Neurotropism in Pancreatic Ductal Adenocarcinoma Cells. Co-author DOI 10.21873/anticanres.14938↗
  5. Tenascin C in the Tumor-Nerve Microenvironment Enhances Perineural Invasion and Correlates With Locoregional Recurrence in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001506↗
  6. Aggressive Recurrent Pancreatic Cancer Producing Granulocyte Colony-Stimulating Factor. Co-author DOI 10.1159/000508439↗
  7. Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1186/s12885-019-5621-5↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshifumi Morita · 7 shared papers, 2019–2026 · strength 1.04
  2. Hiroya Takeuchi · 6 shared papers, 2019–2026 · strength 0.88
  3. Takafumi Suda · 1 shared paper, 2024 · strength 0.17
  4. Kensuke Kitsugi · 1 shared paper, 2024 · strength 0.17
  5. Koji Ikegami · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.